Welcome to our dedicated page for JANUS LIVING news (Ticker: JAN), a resource for investors and traders seeking the latest updates and insights on JANUS LIVING stock.
The news page for JanOne Inc. (historically Nasdaq: JAN) provides an archive of company announcements and press releases that document its transition into ALT5 Sigma Corporation and the evolution of its business focus. These news items explain how the organization moved from being described primarily as a biopharmaceutical company focused on non-addicting pain treatments to a multidisciplinary entity combining healthcare initiatives with a growing fintech platform centered on blockchain-powered digital asset services.
Readers will find coverage of the company’s confirmation of its name change to ALT5 Sigma Corporation and ticker change to ALTS, reflecting a strategic realignment to focus on its recently acquired ALT5 Sigma fintech business as a core engine for revenue growth. News articles describe the acquisition and integration of ALT5 Sigma Inc., the company’s addition to the Russell Microcap Index, and subsequent developments such as the launch of the ALT5 Settlement Platform, the introduction of a prepaid Visa card integration, and reported transaction volumes processed by ALT5 subsidiaries.
The archive also includes updates on leadership appointments related to the fintech business, such as the naming of a Chief Revenue Officer and President for ALT5 Sigma, as well as communications about the company’s ongoing biotech activities aimed at addressing the opioid crisis. Earlier releases highlight JanOne’s efforts to develop non-addicting pain treatments and its dedication to funding innovation, technology, and education in this area.
By reviewing the JAN news feed, investors and researchers can trace key milestones, including the acquisition of ALT5 Sigma, strategic realignment decisions, and subsequent product and platform launches in digital payments and digital asset trading. Because the active Nasdaq ticker has changed from JAN to ALTS, this page serves as a historical record of announcements made under the JAN symbol, complementing more recent disclosures filed under the ALT5 Sigma Corporation identity.
ARCA Recycling, a subsidiary of JanOne, has opened a new appliance recycling center in Pennsauken, New Jersey. This center will process appliances from new programs with electric utilities, aiming to recycle approximately 17,000 refrigerators and freezers annually. The initiative supports energy efficiency programs and is expected to divert over 800 tons of materials from landfills while minimizing ozone-depleting emissions. ARCA Recycling is the largest executor of appliance recycling services in North America, operating more than 90 utility-sponsored programs.
JanOne Inc. (Nasdaq: JAN) has revised its development strategy for its lead drug candidate, JAN101, after receiving feedback from the FDA regarding its Phase 2b clinical trial for treating Peripheral Artery Disease (PAD). Previous studies showed improved vascular function and reduced pain in patients, prompting the development of clinical protocols for the upcoming trial. The FDA's recommendations are expected to enhance the study's effectiveness, with the goal of reducing reliance on opioids for PAD pain management, which affects over 8.5 million Americans.
JanOne Inc. (Nasdaq: JAN) has appointed CPC Clinical Research as the manager for its upcoming Phase 2b clinical trial of JAN101, targeting Peripheral Artery Disease (PAD). The trial will assess the efficacy of two doses of JAN101 in a placebo-controlled study involving 300 diabetic adults over six months. The primary endpoint is the ability to walk without pain, with secondary endpoints including pain reduction and improved blood flow. This trial follows positive results from a prior Phase 2a study, highlighting JanOne's commitment to developing non-addictive pain treatments.
JanOne Inc. (Nasdaq: JAN) has announced that its clinical packaging partner, Xerimis, has received the bottled clinical batch of JAN101 for the Phase 2b trial aimed at treating Peripheral Artery Disease (PAD). The drug is set for distribution to clinical sites across the U.S. Following positive Phase 1 and 2a results, which indicated pain reduction among PAD patients, the company anticipates that JAN101 could yield a multibillion-dollar market opportunity if approved. JanOne aims to provide a non-addictive alternative for the 8.5 million Americans suffering from PAD.
JanOne has selected Avania as its regulatory partner for the upcoming Phase 2b trial of its lead product candidate JAN101, aimed at treating Peripheral Artery Disease (PAD). This collaboration will enhance compliance with FDA requirements, as Avania oversees regulatory operations. The company has also completed the initial batch production of JAN101, marking significant progress towards trial initiation. Following the filing of a pre-Phase 2 briefing package this summer, JanOne anticipates recruiting PAD subjects, potentially benefiting over 8.5 million Americans suffering from this condition.
JanOne Inc. (Nasdaq: JAN) announced the appointment of Dr. Nicholas E. Goeders to its Scientific Advisory Board. Dr. Goeders is a leading expert on stress and addiction, aiming to support JanOne's mission of developing non-addictive pain medications. CEO Tony Isaac emphasized Dr. Goeders' relevance as they advance their treatment for peripheral artery disease (PAD) into Phase 2b clinical trials. JanOne's lead candidate, JAN101, has shown promise in earlier trials, with plans for further development to address the pain and addiction risk associated with opioid prescriptions.
JanOne (Nasdaq: JAN) has engaged DC Consulting LLC to enhance its government and private sector initiatives aimed at pain management. The collaboration targets reducing opioid prescriptions through JanOne's lead candidate, JAN101, which is in the pipeline for Phase 2b trials post positive Phase 2a results. The consulting firm, led by experienced former drug enforcement officials, will assist in legislative and regulatory strategies related to the company's healthcare objectives. JanOne focuses on innovative, non-addictive pain relief solutions, especially for conditions like peripheral artery disease.
JanOne Inc. (Nasdaq: JAN) has successfully completed the CGMP production of the first batch of JAN101, a sustained-release medication aimed at treating Peripheral Artery Disease (PAD). The initial batch produced contains approximately 200,000 tablets and placebos. This marks a significant milestone as JanOne prepares for its Phase 2b trial, focusing on improving vascular function and alleviating neuropathic pain. The FDA-regulated CGMP compliance indicates JanOne's commitment to quality manufacturing. The company also explores the use of JAN101 for other vascular complications.
JanOne Inc. (Nasdaq: JAN) has entered a definitive agreement to sell its subsidiary ARCA Recycling to CFO Virland Johnson for approximately $25 million. This move is part of JanOne's strategy to focus on its core life science assets. The transaction is set to close by August 18, 2021, with immediate payments of $7.5 million and an additional $17.5 million via a subordinated promissory note at 6% interest. Proceeds will support a pivotal Phase 2b trial for the company's lead candidate, JAN101, aimed at treating peripheral artery disease.
JanOne Inc. (Nasdaq: JAN) announced the successful closing of a securities offering, generating $6.0 million in gross proceeds by selling 571,428 shares at $10.50 each to institutional investors. The funds will be allocated for working capital and to plan clinical trials for JAN101, its lead drug candidate aimed at treating peripheral artery disease affecting over 8.5 million Americans. The offering was facilitated by A.G.P./Alliance Global Partners and conducted under a previously filed shelf registration statement.